Although further studies based on more appropriate samplings from patients with meningeal metastases are awaited, the existence of alternative or resistance mechanisms that may be activated in response to the inhibition of the BRAF-driven pathway represents a clear indication that a combination of targeted compounds should be planned for the treatment of melanoma beyond disease progression. This evidence concerns the gene BRAF and melanoma.